Exploring alternative treatments for Helicobacter pylori infection

World Journal of Gastroenterology

Volumn 20, Issue 6, 2014, Pages 1450-1469

  Ayala, Guadalupe ^a   Escobedo Hinojosa, Wendy Itzel ^b   de La Cruz Herrera, Carlos Felipe ^a   Romero, Irma ^b  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Helicobacter pylori; Natural products; Nutraceuticals; Probiotics; Treatment

Indexed keywords

AMOXICILLIN; CAGA PROTEIN; CLARITHROMYCIN; CXCL1 CHEMOKINE; FLAGELLIN; GAMMA INTERFERON; GARLIC EXTRACT; GLYCYRRHIZA EXTRACT; GREEN TEA EXTRACT; INTERLEUKIN 12; INTERLEUKIN 23; KAEMPFEROL; LIPOPOLYSACCHARIDE; LIPOPROTEIN; METRONIDAZOLE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PEPSINOGEN I; PEPTIDOGLYCAN; PROPOLIS; PROTON PUMP INHIBITOR; QUINOLONE; REACTIVE OXYGEN METABOLITE; TETRACYCLINE; TINIDAZOLE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UREASE; VACUOLATING TOXIN; ANTIINFECTIVE AGENT; PROBIOTIC AGENT; STOMACH MUCIN; TEA;

ANTIBACTERIAL ACTIVITY; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL VIRULENCE; BROCCOLI; CD4+ T LYMPHOCYTE; DISEASE COURSE; DISEASE PREDISPOSITION; HELICOBACTER INFECTION; HONEY; HUMAN; IMMUNE RESPONSE; MICROBIAL COLONIZATION; NONHUMAN; PHOTOTHERAPY; PREVALENCE; RED WINE; ULCER HEALING; ALTERNATIVE MEDICINE; ANIMAL; BRASSICA; CHEMISTRY; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; GARLIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; PHYTOTHERAPY; PROCEDURES; TEA; WINE;

ANIMALS; ANTI-BACTERIAL AGENTS; BRASSICA; CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; GARLIC; GASTRIC MUCINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HONEY; HUMANS; PHOTOTHERAPY; PHYTOTHERAPY; PROBIOTICS; PROPOLIS; TEA; WINE;

EID: 84893801300     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i6.1450     Document Type: Article

References (210)

1. Clyne M, Dolan B, Reeves EP. Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol Lett 2007; 268: 135-143 [PMID: 17313591 DOI: 10.1111/j.1574-6968.2007.00648.x]
2. Dunn BE, Campbell GP, Perez-Perez GI, Blaser MJ. Purification and characterization of urease from Helicobacter pylori. J Biol Chem 1990; 265: 9464-9469 [PMID: 2188975]
3. Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun 1994; 62: 3604-3607 [PMID: 8063376]
4. Harris PR, Mobley HL, Perez-Perez GI, Blaser MJ, Smith PD. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. Gastroenterology 1996; 111: 419-425 [PMID: 8690207 DOI: 10.1053/gast.1996.v111.pm8690207]
5. Koch KS, Leffert HL.Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. Hepat Med 2010; 2010: 39-47 [PMID: 23997575 DOI: 10.1128/IAI.74.2.1148-1155.2006]
6. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Borén T. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373-377 [PMID: 9430586 DOI: 10.1126/science.279.5349.373]
7. Mahdavi J, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S Wadström T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarström L, Borén T. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573-578 [PMID: 12142529 DOI: 10.1126/science.1069076]
8. Israel DA, Peek RM. Pathogenesis of Helicobacter pyloriinduced gastric inflammation. Aliment Pharmacol Ther 2001; 15: 1271-1290 [PMID: 11552897 DOI: 10.1046/ j.1365-2036.2001.01052.x]
9. Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehlke S, Classen M, Prinz C. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA 1999; 96: 12778-12783 [PMID: 10535999 DOI: 10.1073/pnas.96.22.12778]
10. Prinz C, Schöniger M, Rad R, Becker I, Keiditsch E, Wagenpfeil S, Classen M, Rösch T, Schepp W, Gerhard M. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation. Cancer Res 2001; 61: 1903-1909 [PMID: 11280745]
11. Senkovich OA, Yin J, Ekshyyan V, Conant C, Traylor J, Adegboyega P, McGee DJ, Rhoads RE, Slepenkov S, Testerman TL. Helicobacter pylori AlpA and AlpB bind host laminin and influence gastric inflammation in gerbils. Infect Immun 2011; 79: 3106-3116 [PMID: 21576328 DOI: 10.1128/ IAI.01275-10]
12. Peck B, Ortkamp M, Diehl KD, Hundt E, Knapp B. Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori. Nucleic Acids Res 1999; 27: 3325-3333 [PMID: 10454640 DOI: 10.1093/ nar/27.16.3325]
13. Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci USA 2000; 97: 7533-7538 [PMID: 10852959 DOI: 10.1073/pnas.130079797]
14. Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123: 414-424 [PMID: 12145793 DOI: 10.1053/gast.2002.34781]
15. Hessey SJ, Spencer J, Wyatt JI, Sobala G, Rathbone BJ, Axon AT, Dixon MF. Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis. Gut 1990; 31: 134-138 [PMID: 2311970 DOI: 10.1136/gut.31.2.134]
16. Tonello F, Dundon WG, Satin B, Molinari M, Tognon G, Grandi G, Del Giudice G, Rappuoli R, Montecucco C. The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. Mol Microbiol 1999; 34: 238-246 [PMID: 10564468 DOI: 10.1046/ j.1365-2958.1999.01584.x]
17. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000; 191: 1467-1476 [PMID: 10790422 DOI: 10.1084/ jem.191.9.1467]
18. Polenghi A, Bossi F, Fischetti F, Durigutto P, Cabrelle A, Tamassia N, Cassatella MA, Montecucco C, Tedesco F, de Bernard M. The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 2007; 178: 1312-1320 [PMID: 17237377]
19. Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, Tasca E, Azzurri A, D'Elios MM, Del Prete G, de Bernard M. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006; 116: 1092-1101 [PMID: 16543949 DOI: 10.1172/ JCI27177]
20. Stent A, Every AL, Sutton P. Helicobacter pylori defense against oxidative attack. Am J Physiol Gastrointest Liver Physiol 2012; 302: G579-G587 [PMID: 22194421 DOI: 10.1152/ ajpgi.00495.2011]
21. Lundström AM, Sundaeus V, Bölin I. The 26-kilodalton, AhpC homologue, of Helicobacter pylori is also produced by other Helicobacter species. Helicobacter 2001; 6: 44-54 [PMID: 11328365 DOI: 10.1046/j.1523-5378.2001.00006.x]
22. Wang G, Conover RC, Benoit S, Olczak AA, Olson JW, Johnson MK, Maier RJ. Role of a bacterial organic hydroperoxide detoxification system in preventing catalase inactivation. J Biol Chem 2004; 279: 51908-51914 [PMID: 15456778 DOI: 10.1074/jbc.M408450200]
23. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-323 [PMID: 18166359]
24. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301 [PMID: 9135515]
25. Iwamoto H, Czajkowsky DM, Cover TL, Szabo G, Shao Z. VacA from Helicobacter pylori: a hexameric chloride channel. FEBS Lett 1999; 450: 101-104 [PMID: 10350065 DOI: 10.1016/S0014-5793(99)00474-3]
26. Tombola F, Morbiato L, Del Giudice G, Rappuoli R, Zoratti M, Papini E. The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 2001; 108: 929-937 [PMID: 11560962 DOI: 10.1172/JCI200113045]
27. Papini E, Satin B, Norais N, de Bernard M, Telford JL, Rappuoli R, Montecucco C. Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin. J Clin Invest 1998; 102: 813-820 [PMID: 9710450 DOI: 10.1172/JCI2764]
28. Molinari M, Salio M, Galli C, Norais N, Rappuoli R, Lanzavecchia A, Montecucco C. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J Exp Med 1998; 187: 135-140 [PMID: 9419220 DOI: 10.1084/ jem.187.1.135]
29. Yamasaki E, Wada A, Kumatori A, Nakagawa I, Funao J, Nakayama M, Hisatsune J, Kimura M, Moss J, Hirayama T. Helicobacter pylori vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome c release and cell death, independent of vacuolation. J Biol Chem 2006; 281: 11250-11259 [PMID: 16436379 DOI: 10.1074/jbc.M509404200]
30. Torres VJ, VanCompernolle SE, Sundrud MS, Unutmaz D, Cover TL. Helicobacter pylori vacuolating cytotoxin inhibits activation-induced proliferation of human T and B lymphocyte subsets. J Immunol 2007; 179: 5433-5440 [PMID: 17911630]
31. Sewald X, Gebert-Vogl B, Prassl S, Barwig I, Weiss E, Fabbri M, Osicka R, Schiemann M, Busch DH, Semmrich M, Holzmann B, Sebo P, Haas R. Integrin subunit CD18 Is the T-lymphocyte receptor for the Helicobacter pylori vacuolating cytotoxin. Cell Host Microbe 2008; 3: 20-29 [PMID: 18191791 DOI: 10.1016/j.chom.2007.11.003]
32. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648-14653 [PMID: 8962108 DOI: 10.1073/ pnas.93.25.14648]
33. Rohde M, Püls J, Buhrdorf R, Fischer W, Haas R. A novel sheathed surface organelle of the Helicobacter pylori cag type IV secretion system. Mol Microbiol 2003; 49: 219-234 [PMID: 12823823 DOI: 10.1046/j.1365-2958.2003.03549.x]
34. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, Misselwitz R, Berger J, Sewald N, König W, Backert S. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 2007; 449: 862-866 [PMID: 17943123 DOI: 10.1038/nature06187]
35. Conradi J, Tegtmeyer N, Woźna M, Wissbrock M, Michalek C, Gagell C, Cover TL, Frank R, Sewald N, Backert S. An RGD helper sequence in CagL of Helicobacter pylori assists in interactions with integrins and injection of CagA. Front Cell Infect Microbiol 2012; 2: 70 [PMID: 22919661 DOI: 10.3389/fcimb.2012.00070.]
36. Gorrell RJ, Guan J, Xin Y, Tafreshi MA, Hutton ML, McGuckin MA, Ferrero RL, Kwok T. A novel NOD1-and CagA-independent pathway of interleukin-8 induction mediated by the Helicobacter pylori type IV secretion system. Cell Microbiol 2012 Oct 26; Epub ahead of print [PMID: 23107019 DOI: 10.1111/cmi.12055]
37. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23: 713-739 [PMID: 20930071 DOI: 10.1128/CMR.00011-10]
38. Suzuki M, Mimuro H, Suzuki T, Park M, Yamamoto T, Sasakawa C. Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion. J Exp Med 2005; 202: 1235-1247 [PMID: 16275761 DOI: 10.1084/jem.20051027]
39. Selbach M, Moese S, Hurwitz R, Hauck CR, Meyer TF, Backert S. The Helicobacter pylori CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. EMBO J 2003; 22: 515-528 [PMID: 12554652 DOI: 10.1093/emboj/cdg050]
40. Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 2003; 161: 249-255 [PMID: 12719469 DOI: 10.1083/ jcb.200208039]
41. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 1430-1434 [PMID: 12775840 DOI: 10.1126/science.1081919]
42. Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, Lu H, Ohnishi N, Azuma T, Suzuki A, Ohno S, Hatakeyama M. Helicobacter pylori CagA targets PAR1/ MARK kinase to disrupt epithelial cell polarity. Nature 2007; 447: 330-333 [PMID: 17507984 DOI: 10.1038/nature05765]
43. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM, Azuma T, Hatakeyama M. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 2007; 26: 4617-4626 [PMID: 17237808 DOI: 10.1038/sj.onc.1210251]
44. Brandt S, Kwok T, Hartig R, König W, Backert S. NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 2005; 102: 9300-9305 [PMID: 15972330 DOI: 10.1073/ pnas.0409873102]
45. Pillinger MH, Marjanovic N, Kim SY, Lee YC, Scher JU, Roper J, Abeles AM, Izmirly PI, Axelrod M, Pillinger MY, Tolani S, Dinsell V, Abramson SB, Blaser MJ. Helicobacter pylori stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and -independent ERK activation. J Biol Chem 2007; 282: 18722-18731 [PMID: 17475625 DOI: 10.1074/ jbc.M703022200]
46. Arachchi HS, Kalra V, Lal B, Bhatia V, Baba CS, Chakravarthy S, Rohatgi S, Sarma PM, Mishra V, Das B, Ahuja V. Prevalence of duodenal ulcer-promoting gene (dupA) of Helicobacter pylori in patients with duodenal ulcer in North Indian population. Helicobacter 2007; 12: 591-597 [PMID: 18001398 DOI: 10.1111/j.1523-5378.2007.00557.x]
47. Douraghi M, Mohammadi M, Oghalaie A, Abdirad A, Mohagheghi MA, Hosseini ME, Zeraati H, Ghasemi A, Esmaieli M, Mohajerani N. dupA as a risk determinant in Helicobacter pylori infection. J Med Microbiol 2008; 57: 554-562 [PMID: 18436587 DOI: 10.1099/jmm.0.47776-0]
48. Argent RH, Burette A, Miendje Deyi VY, Atherton JC. The presence of dupA in Helicobacter pylori is not significantly associated with duodenal ulceration in Belgium, South Africa, China, or North America. Clin Infect Dis 2007; 45: 1204-1206 [PMID: 17918084 DOI: 10.1086/522177]
49. Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008; 3: 352-363 [PMID: 18541212 DOI: 10.1016/j.chom.2008.05.003]
50. Takeda K, Akira S. Toll receptors and pathogen resistance. Cell Microbiol 2003; 5: 143-153 [PMID: 12614458 DOI: 10.1046/j.1462-5822.2003.00264.x]
51. Brodsky IE, Monack D. NLR-mediated control of inflamma some assembly in the host response against bacterial pathogens. Semin Immunol 2009; 21: 199-207 [PMID: 19539499 DOI: 10.1016/j.smim.2009.05.007]
52. Muotiala A, Helander IM, Pyhälä L, Kosunen TU, Moran AP. Low biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun 1992; 60: 1714-1716 [PMID: 1548097]
53. Bliss CM, Golenbock DT, Keates S, Linevsky JK, Kelly CP. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infect Immun 1998; 66: 5357-5363 [PMID: 9784544]
54. Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004; 189: 1914-1920 [PMID: 15122529 DOI: 10.1086/386289]
55. Lee SK, Stack A, Katzowitsch E, Aizawa SI, Suerbaum S, Josenhans C. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003; 5: 1345-1356 [PMID: 14670447 DOI: 10.1016/j.micinf.2003.09.018]
56. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Mémet S, Huerre MR, Coyle AJ, DiStefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5: 1166-1174 [PMID: 15489856 DOI: 10.1038/ni1131]
57. Kaparakis M, Turnbull L, Carneiro L, Firth S, Coleman HA, Parkington HC, Le Bourhis L, Karrar A, Viala J, Mak J, Hutton ML, Davies JK, Crack PJ, Hertzog PJ, Philpott DJ, Girardin SE, Whitchurch CB, Ferrero RL. Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells. Cell Microbiol 2010; 12: 372-385 [PMID: 19888989 DOI: 10.1111/j.1462-5822.2009.01404.x]
58. Kim YG, Park JH, Shaw MH, Franchi L, Inohara N, Núñez G. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Tolllike receptor ligands. Immunity 2008; 28: 246-257 [PMID: 18261938 DOI: 10.1016/j.immuni.2007.12.012]
59. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007; 133: 288-308 [PMID: 17631150 DOI: 10.1053/j.gastro.2007.05.008]
60. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998; 188: 2277-2288 [PMID: 9858514 DOI: 10.1084/ jem.188.12.2277]
61. Hitzler I, Oertli M, Becher B, Agger EM, Müller A. Dendritic cells prevent rather than promote immunity conferred by a Helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology 2011; 141: 186-196, 196.e1 [PMID: 21569773 DOI: 10.1053/j.gastro.2011.04.009]
62. Akhiani AA, Pappo J, Kabok Z, Schön K, Gao W, Franzén LE, Lycke N. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002; 169: 6977-6984 [PMID: 12471132]
63. Sayi A, Kohler E, Hitzler I, Arnold I, Schwendener R, Rehrauer H, Müller A. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 2009; 182: 7085-7101 [PMID: 19454706 DOI: 10.4049/jimmunol.0803293]
64. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E, Bouzourene H, Michetti P. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009; 136: 2237-2246.e1 [PMID: 19272385 DOI: 10.1053/ j.gastro.2009.02.077]
65. Wan YY, Flavell RA. How diverse--CD4 effector T cells and their functions. J Mol Cell Biol 2009; 1: 20-36 [PMID: 19482777 DOI: 10.1093/jmcb/mjp001]
66. Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter 2011; 16: 1-8 [PMID: 21241406 DOI: 10.1111/j.1523-5378.2010.00812.x]
67. Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 2013; 11: 385-399 [PMID: 23652324 DOI: 10.1038/nrmicro3016]
68. O'Keeffe J, Moran AP. Conventional, regulatory, and unconventional T cells in the immunologic response to Helicobacter pylori. Helicobacter 2008; 13: 1-19 [PMID: 18205661 DOI: 10.1111/j.1523-5378.2008.00559.x]
69. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, Maxeiner J, Hansson M, Taube C, Quiding-Järbrink M, Müller A. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 2012; 122: 1082-1096 [PMID: 22307326 DOI: 10.1172/JCI61029]
70. Enarsson K, Lundgren A, Kindlund B, Hermansson M, Roncador G, Banham AH, Lundin BS, Quiding-Järbrink M. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 2006; 121: 358-368 [PMID: 16934529 DOI: 10.1016/j.clim.2006.07.002]
71. Lundin BS, Enarsson K, Kindlund B, Lundgren A, Johnsson E, Quiding-Järbrink M, Svennerholm AM. The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol 2007; 125: 205-213 [PMID: 17826353 DOI: 10.1016/ j.clim.2007.07.011]
72. Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding Järbrink M. CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur J Immunol 2007; 37: 282-291 [PMID: 17163448 DOI: 10.1002/ eji.200636183]
73. Li X, Kostareli E, Suffner J, Garbi N, Hämmerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 2010; 40: 3325-3335 [PMID: 21072887 DOI: 10.1002/eji.201041093]
74. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010; 70: 7800-7809 [PMID: 20924111 DOI: 10.1158/0008-5472. CAN-10-1681]
75. Hamlet A, Thoreson AC, Nilsson O, Svennerholm AM, Olbe L. Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology 1999; 116: 259-268 [PMID: 9922305 DOI: 10.1016/S0016-5085(99)70121-6]
76. Kindlund B, Sjöling A, Hansson M, Edebo A, Hansson LE, Sjövall H, Svennerholm AM, Lundin BS. FOXP3-expressing CD4(+) T-cell numbers increase in areas of duodenal gastric metaplasia and are associated to CD4(+) T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter 2009; 14: 192-201 [PMID: 19702849 DOI: 10.1111/j.1523-5378.2009.00673.x]
77. Strömberg E, Edebo A, Svennerholm AM, Lindholm C. Decreased epithelial cytokine responses in the duodenal mucosa of Helicobacter pylori-infected duodenal ulcer patients. Clin Diagn Lab Immunol 2003; 10: 116-124 [PMID: 12522049 DOI: 10.1128/CDLI.10.1.116-124.2003]
78. Khulusi S, Badve S, Patel P, Lloyd R, Marrero JM, Finlayson C, Mendall MA, Northfield TC. Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology 1996; 110: 452-458 [PMID: 8566592 DOI: 10.1053/gast.1996.v110. pm8566592]
79. Cheung TK, Wong BC. Treatment of Helicobacter pylori and prevention of gastric cancer. J Dig Dis 2008; 9: 8-13 [PMID: 18251788 DOI: 10.1111/j.1443-9573.2007.00315.x]
80. Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol 2008; 23: 1666-1671 [PMID: 17559360]
81. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, ElOmar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
82. Coelho LG, León-Barúa R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95: 2688-2691 [PMID: 11051336 DOI: 10.1111/j.1572-0241.2000.03174.x]
83. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]
84. Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol 2010; 26: 618-623 [PMID: 20827182 DOI: 10.1097/ MOG.0b013e32833efede]
85. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
86. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-331 [PMID: 18446147 DOI: 10.1038/ncpgasthep1138]
87. Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol 2010; 5: 639-648 [PMID: 20353303 DOI: 10.2217/fmb.10.25]
88. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 2007; 12: 89-102 [PMID: 17309745 DOI: 10.1111/j.1523-5378.2007.00478.x]
89. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008; 135: 787-795 [PMID: 18619971 DOI: 10.1053/ j.gastro.2008.05.054]
90. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQdeleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-459 [PMID: 10519934 DOI: 10.1016/S0264-410X(99)00246-7]
91. Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, Haas G, Aebischer T, von Specht BU, Meyer TF. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001; 20: 845-852 [PMID: 11738748 DOI: 10.1016/S0264410X(01)00391-7]
92. Metzger WG, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R, Bumann D, Aebischer T, Von Specht BU, Meyer TF. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004; 22: 2273-2277 [PMID: 15149786 DOI: 10.1016/j.vaccine.2003.11.020]
93. Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G, Walduck AK, Kunkel D, Moos V, Loddenkemper C, Jiadze I, Panasyuk M, Stolte M, Graham DY, Zeitz M, Meyer TF. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 2008; 57: 1065-1072 [PMID: 18417532 DOI: 10.1136/gut.2007.145839]
94. Yan J, Mao YF, Shao ZX. Frequencies of the expression of main protein antigens from Helicobacter pylori isolates and production of specific serum antibodies in infected patients. World J Gastroenterol 2005; 11: 421-425 [PMID: 15637759]
95. Lepper PM, Möricke A, Vogt K, Bode G, Trautmann M. Comparison of different criteria for interpretation of immunoglobulin G immunoblotting results for diagnosis of Helicobacter pylori infection. Clin Diagn Lab Immunol 2004; 11: 569-576 [PMID: 15138184 DOI: 10.1128/ CDLI.11.3.569-576.2004]
96. Flach CF, Svensson N, Blomquist M, Ekman A, Raghavan S, Holmgren J. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 2011; 29: 1235-1241 [PMID: 21147129 DOI: 10.1016/ j.vaccine.2010.11.088]
97. Wang L, Liu XF, Yun S, Yuan XP, Mao XH, Wu C, Zhang WJ, Liu KY, Guo G, Lu DS, Tong WD, Wen AD, Zou QM. Protection against Helicobacter pylori infection by a trivalent fusion vaccine based on a fragment of urease B-UreB414. J Microbiol 2010; 48: 223-228 [PMID: 20437155 DOI: 10.1007/ s12275-009-0233-4]
98. Iankov ID, Haralambieva IH, Galanis E. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 2011; 29: 1710-1720 [PMID: 21182995 DOI: 10.1016/ j.vaccine.2010.12.020]
99. Every AL, Stent A, Moloney MB, Ng GZ, Skene CD, Edwards SJ, Sutton P. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2011; 29: 1514-1518 [PMID: 21172379 DOI: 10.1016/j.vaccine.2010.12.019]
100. Stent A, Every AL, Ng GZ, Chionh YT, Ong LS, Edwards SJ, Sutton P. Helicobacter pylori thiolperoxidase as a protective antigen in singleand multi-component vaccines. Vaccine 2012; 30: 7214-7220 [PMID: 23084846 DOI: 10.1016/ j.vaccine.2012.10.022]
101. Blanchard TG, Eisenberg JC, Matsumoto Y. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 2004; 22: 888-897 [PMID: 15040942 DOI: 10.1016/ j.vaccine.2003.11.035]
102. Rossi G, Ruggiero P, Peppoloni S, Pancotto L, Fortuna D, Lauretti L, Volpini G, Mancianti S, Corazza M, Taccini E, Di Pisa F, Rappuoli R, Del Giudice G. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 2004; 72: 3252-3259 [PMID: 15155627 DOI: 10.1128/ IAI.72.6.3252-3259.2004]
103. Jeremy AH, Du Y, Dixon MF, Robinson PA, Crabtree JE. Protection against Helicobacter pylori infection in the Mongolian gerbil after prophylactic vaccination. Microbes Infect 2006; 8: 340-346 [PMID: 16213184 DOI: 10.1016/ j.micinf.2005.06.025]
104. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine 2012; 30: 5310-5315 [PMID: 22749593 DOI: 10.1016/j.vaccine.2012.06.052]
105. Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003; 71: 1755-1762 [PMID: 12654789 DOI: 10.1128/IAI.71.4.1755-1762.2003]
106. Raghavan S, Suri-Payer E, Holmgren J. Antigen-specific in vitro suppression of murine Helicobacter pylori-reactive immunopathological T cells by CD4CD25 regulatory T cells. Scand J Immunol 2004; 60: 82-88 [PMID: 15238076 DOI: 10.1111/j.0300-9475.2004.01447.x]
107. Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2011; 8: 133-140 [PMID: 21304478 DOI: 10.1038/nrgastro.2011.1]
108. Al Mofleh IA. Spices, herbal xenobiotics and the stomach: friends or foes? World J Gastroenterol 2010; 16: 2710-2719 [PMID: 20533590 DOI: 10.3748/wjg.v16.i22.2710]
109. Cassel-Beraud AM, Le Jan J, Mouden JC, Andriantsoa M, Andriantsiferana R. Preliminary study of the prevalence of Helicobacter pylori in Tananarive, Madagascar and the antibacterial activity in vitro of 13 Malagasy medicinal plants on this germ. Arch Inst Pasteur Madagascar 1991; 59: 9-23 [PMID: 1669364]
110. Higuchi K, Arakawa T, Ando K, Fujiwara Y, Uchida T, Kuroki T. Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies. Am J Gastroenterol 1999; 94: 1419-1420 [PMID: 10235237 DOI: 10.1111/j.1572-0241.1999.01419.x]
111. Ankli A, Heinrich M, Bork P, Wolfram L, Bauerfeind P, Brun R, Schmid C, Weiss C, Bruggisser R, Gertsch J, Wasescha M, Sticher O. Yucatec Mayan medicinal plants: evaluation based on indigenous uses. J Ethnopharmacol 2002; 79: 43-52 [PMID: 11744294 DOI: 10.1016/S0378-8741(01)00355-5]
112. Castillo-Juárez I, González V, Jaime-Aguilar H, Martínez G, Linares E, Bye R, Romero I. Anti-Helicobacter pylori activity of plants used in Mexican traditional medicine for gastrointestinal disorders. J Ethnopharmacol 2009; 122: 402-405 [PMID: 19162157 DOI: 10.1016/j.jep.2008.12.021]
113. Robles-Zepeda RE, Velázquez-Contreras CA, Garibay-Escobar A, Gálvez-Ruiz JC, Ruiz-Bustos E. Antimicrobial activity of Northwestern Mexican plants against Helicobacter pylori. J Med Food 2011; 14: 1280-1283 [PMID: 21663492 DOI: 10.1089/jmf.2010.0263]
114. Nariman F, Eftekhar F, Habibi Z, Falsafi T. Anti-Helicobacter pylori activities of six Iranian plants. Helicobacter 2004; 9: 146-151 [PMID: 15068416 DOI: 10.1111/j.1083-4389.2004.00211.x]
115. Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi F, Mehrabani M, Hosseinzadeh H, Foroumadi P, Safavi M, Khanavi M, Akbarzadeh T, Shafiee A, Foroumadi A. In vitro antibacterial activity of some Iranian medicinal plant extracts against Helicobacter pylori. Nat Prod Res 2011; 25: 1059-1066 [PMID: 21726128 DOI: 10.1080/14786419.2010.501763]
116. Wang YC, Huang TL. Screening of anti-Helicobacter pylori herbs deriving from Taiwanese folk medicinal plants. FEMS Immunol Med Microbiol 2005; 43: 295-300 [PMID: 15681161 DOI: 10.1016/j.femsim.2004.09.008]
117. Fabry W, Okemo P, Ansorg R. Activity of east African medicinal plants against Helicobacter pylori. Chemotherapy 1996; 42: 315-317 [PMID: 8874968 DOI: 10.1159/000239460]
118. Ndip RN, Malange Tarkang AE, Mbullah SM, Luma HN, Malongue A, Ndip LM, Nyongbela K, Wirmum C, Efange SM. In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. J Ethnopharmacol 2007; 114: 452-457 [PMID: 17913416 DOI: 10.1016/j.jep.2007.08.037]
119. Stamatis G, Kyriazopoulos P, Golegou S, Basayiannis A, Skaltsas S, Skaltsa H. In vitro anti-Helicobacter pylori activity of Greek herbal medicines. J Ethnopharmacol 2003; 88: 175-179 [PMID: 12963139 DOI: 10.1016/S0378-8741(03)00217-4]
120. Kawase M, Motohashi N. Plant-derived leading compounds for eradication of Helicobacter pylori. Curr Med Chem-Anti-Infective Agents 2004; 3: 89-100 [DOI: 10.2174/1568012043353 982]
121. Castillo-Juárez I, Romero I. Plantas con actividad anti-Helicobacter pylori: una revisión. Bol Soc Bot Mex 2007; 80: 35-62
122. Mabe K, Yamada M, Oguni I, Takahashi T. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1788-1791 [PMID: 10390246]
123. Koga T, Inoue H, Ishii C, Okazaki Y, Domon H, Utsui Y. Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo. J Antimicrob Chemother 2002; 50: 133-136 [PMID: 12096020 DOI: 10.1093/jac/dkf094]
124. Tominaga K, Higuchi K, Hamasaki N, Hamaguchi M, Takashima T, Tanigawa T, Watanabe T, Fujiwara Y, Tezuka Y, Nagaoka T, Kadota S, Ishii E, Kobayashi K, Arakawa T. In vivo action of novel alkyl methyl quinolone alkaloids against Helicobacter pylori. J Antimicrob Chemother 2002; 50: 547-552 [PMID: 12356800 DOI: 10.1093/jac/dkf159]
125. Kataoka M, Hirata K, Kunikata T, Ushio S, Iwaki K, Ohashi K, Ikeda M, Kurimoto M. Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (Polygonum tinctorium Lour.), against Helicobacter pylori-infected Mongolian gerbils. J Gastroenterol 2001; 36: 5-9 [PMID: 11211212 DOI: 10.1007/s005350170147]
126. Haristoy X, Angioi-Duprez K, Duprez A, Lozniewski A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrob Agents Chemother 2003; 47: 3982-3984 [PMID: 14638516 DOI: 10.1128/AAC.47.12.3982-3984.2003]
127. Yanaka A. Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pylori-infected gastric mucosae in mice and human subjects. Curr Pharm Des 2011; 17: 1532-1540 [PMID: 21548875 DOI: 10.2174 /138161211796196945]
128. Cao X, Tsukamoto T, Seki T, Tanaka H, Morimura S, Cao L, Mizoshita T, Ban H, Toyoda T, Maeda H, Tatematsu M. 4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils. Int J Cancer 2008; 122: 1445-1454 [PMID: 18059022 DOI: 10.1002/ ijc.23245]
129. Goswami S, Bhakuni RS, Chinniah A, Pal A, Kar SK, Das PK. Anti-Helicobacter pylori potential of artemisinin and its derivatives. Antimicrob Agents Chemother 2012; 56: 4594-4607 [PMID: 22687518 DOI: 10.1128/AAC.00407-12]
130. Lima ZP, dos Santos Rde C, Torres TU, Sannomiya M, Rodrigues CM, dos Santos LC, Pellizzon CH, Rocha LR, Vilegas W, Souza Brito AR, Cardoso CR, Varanda EA, de Moraes HP, Bauab TM, Carli C, Carlos IZ, Hiruma-Lima CA. Byrsonima fagifolia: an integrative study to validate the gastroprotective, healing, antidiarrheal, antimicrobial and mutagenic action. J Ethnopharmacol 2008; 120: 149-160 [PMID: 18761075 DOI: 10.1016/j.jep.2008.07.047]
131. Mazzolin LP, Nasser AL, Moraes TM, Santos RC, Nishijima CM, Santos FV, Varanda EA, Bauab TM, da Rocha LR, Di Stasi LC, Vilegas W, Hiruma-Lima CA. Qualea parviflora Mart.: an integrative study to validate the gastroprotective, antidiarrheal, antihemorragic and mutagenic action. J Ethno-pharmacol 2010; 127: 508-514 [PMID: 19833186 DOI: 10.1016/ j.jep.2009.10.005]
132. Moleiro FC, Andreo MA, Santos Rde C, Moraes Tde M, Rodrigues CM, Carli CB, Lopes FC, Pellizzon CH, Carlos IZ, Bauab TM, Vilegas W, Hiruma-Lima CA. Mouririelliptica: validation of gastroprotective, healing and anti-Helicobacter pylori effects. J Ethnopharmacol 2009; 123: 359-368 [PMID: 19501267 DOI: 10.1016/j.jep.2009.03.040]
133. Escobedo-Hinojosa WI, Del Carpio JD, Palacios-Espinosa JF, Romero I. Contribution to the ethnopharmacological and anti-Helicobacter pylori knowledge of Cyrtocarpa procera Kunth (Anacardiaceae). J Ethnopharmacol 2012; 143: 363-371 [PMID: 22796202 DOI: 10.1016/j.jep.2012.07.001]
134. Amin M, Anwar F, Naz F, Mehmood T, Saari N. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. Molecules 2013; 18: 2135-2149 [PMID: 23434867 DOI: 10.3390/molecules18022135]
135. Asha MK, Debraj D, Prashanth D, Edwin JR, Srikanth HS, Muruganantham N, Dethe SM, Anirban B, Jaya B, Deepak M, Agarwal A. In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action. J Ethnopharmacol 2013; 145: 581-586 [PMID: 23220194 DOI: 10.1016/j.jep.2012.11.033]
136. Niehues M, Euler M, Georgi G, Mank M, Stahl B, Hensel A. Peptides from Pisum sativum L. enzymatic protein digest with anti-adhesive activity against Helicobacter pylori: structure-activity and inhibitory activity against BabA, SabA, HpaA and a fibronectin-binding adhesin. Mol Nutr Food Res 2010; 54: 1851-1861 [PMID: 20540145 DOI: 10.1002/ mnfr.201000021]
137. Wittschier N, Faller G, Hensel A. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach. Phytomedicine 2007; 14: 285-288 [PMID: 17350240 DOI: 10.1016/j.phymed.2006.12.008]
138. O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, Vaira D, Holton J, Basset C. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J Gastroenterol 2005; 11: 7499-7507 [PMID: 16437723]
139. Ruggiero P, Tombola F, Rossi G, Pancotto L, Lauretti L, Del Giudice G, Zoratti M. Polyphenols reduce gastritis induced by Helicobacter pylori infection or VacA toxin administration in mice. Antimicrob Agents Chemother 2006; 50: 2550-2552 [PMID: 16801443 DOI: 10.1128/AAC.01042-05]
140. Tombola F, Campello S, De Luca L, Ruggiero P, Del Giudice G, Papini E, Zoratti M. Plant polyphenols inhibit VacA, a toxin secreted by the gastric pathogen Helicobacter pylori. FEBS Lett 2003; 543: 184-189 [PMID: 12753930 DOI: 10.1016/ S0014-5793(03)00443-5]
141. Liu JS, Cheng WC, Wang HJ, Chen YC, Wang WC. Structure-based inhibitor discovery of Helicobacter pylori dehy-droquinate synthase. Biochem Biophys Res Commun 2008; 373: 1-7 [PMID: 18503755 DOI: 10.1016/j.bbrc.2008.05.070]
142. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996; 96: 1027-1039 [PMID: 8841165 DOI: 10.1016/S0002-8223(96)00273-8]
143. Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N. Inhibition of Helicobacter pylori by garlic extract (Allium sativum). FEMS Immunol Med Microbiol 1996; 13: 273-277 [PMID: 8739190 DOI: 10.1111/j.1574-695X.1996.tb00251.x]
144. Sivam GP, Lampe JW, Ulness B, Swanzy SR, Potter JD. Helicobacter pylori--in vitro susceptibility to garlic (Allium sativum) extract. Nutr Cancer 1997; 27: 118-121 [PMID: 9121937 DOI: 10.1080/01635589709514512]
145. Chung JG, Chen GW, Wu LT, Chang HL, Lin JG, Yeh CC, Wang TF. Effects of garlic compounds diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Am J Chin Med 1998; 26: 353-364 [PMID: 9862023 DOI: 10.1142/ S0192415X98000397]
146. Cañizares P, Gracia I, Gómez LA, Martín de Argila C, Boixeda D, García A, de Rafael L. Allyl-thiosulfinates, the bacteriostatic compounds of garlic against Helicobacter pylori. Biotechnol Prog 2004; 20: 397-401 [PMID: 14763870 DOI: 10.1021/bp034143b]
147. Mahady GB, Matsuura H, Pendland SL. Allixin, a phytoalexin from garlic, inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol 2001; 96: 3454-3455 [PMID: 11774979 DOI: 10.1111/j.1572-0241.2001.05351.x]
148. Tabak M, Armon R, Potasman I, Neeman I. In vitro inhibition of Helicobacter pylori by extracts of thyme. J Appl Bacteriol 1996; 80: 667-672 [PMID: 8698668 DOI: 10.1111/ j.1365-2672.1996.tb03272.x]
149. Ohta R, Yamada N, Kaneko H, Ishikawa K, Fukuda H, Fujino T, Suzuki A. In vitro inhibition of the growth of Helico-bacter pylori by oil-macerated garlic constituents. Antimicrob Agents Chemother 1999; 43: 1811-1812 [PMID: 10438335]
150. Graham DY, Anderson SY, Lang T. Garlic or jalapeño peppers for treatment of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1200-1202 [PMID: 10235193 DOI: 10.1111/ j.1572-0241.1999.01066.x]
151. McNulty CA, Wilson MP, Havinga W, Johnston B, O'Gara EA, Maslin DJ. A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter pylori. Helicobacter 2001; 6: 249-253 [PMID: 11683929 DOI: 10.1046/j.1523-5378.2001.00036.x]
152. Iimuro M, Shibata H, Kawamori T, Matsumoto T, Arakawa T, Sugimura T, Wakabayashi K. Suppressive effects of garlic extract on Helicobacter pylori-induced gastritis in Mongolian gerbils. Cancer Lett 2002; 187: 61-68 [PMID: 12359352 DOI: 10.1016/S0304-3835(02)00401-9]
153. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, Xu GW, Gail MH. Randomized doubleblind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-983 [PMID: 16849680 DOI: 10.1093/jnci/djj264]
154. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, You WC, Gail MH. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104: 488-492 [PMID: 22271764 DOI: 10.1093/jnci/djs003]
155. Yassibaş E, Arslan P, Yalçin S. Evaluation of dietary and life-style habits of patients with gastric cancer: a case-control study in Turkey. Asian Pac J Cancer Prev 2012; 13: 2291-2297 [PMID: 22901209 DOI: 10.7314/APJCP.2012.13.5.2291]
156. Galan MV, Kishan AA, Silverman AL. Oral broccoli sprouts for the treatment of Helicobacter pylori infection: a preliminary report. Dig Dis Sci 2004; 49: 1088-1090 [PMID: 15387326 DOI: 10.1023/B:DDAS.0000037792.04787.8a]
157. Opekun AR, Yeh CW, Opekun JL, Graham DY. In vivo tests of natural therapy, Tibetan yogurt or fresh broccoli, for Helicobacter pylori infection. Methods Find Exp Clin Pharmacol 2005; 27: 327-329 [PMID: 16082421 DOI: 10.1358/ mf.2005.27.5.896760]
158. Sato K, Kawakami N, Ohtsu T, Tsutsumi A, Miyazaki S, Masumoto T, Horie S, Haratani T, Kobayashi F, Araki S. Broccoli consumption and chronic atrophic gastritis among Japanese males: an epidemiological investigation. Acta Med Okayama 2004; 58: 127-133 [PMID: 15471434]
159. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyreneinduced stomach tumors. Proc Natl Acad Sci USA 2002; 99: 7610-7615 [PMID: 12032331 DOI: 10.1073/pnas.112203099]
160. Stoicov C, Saffari R, Houghton J. Green tea inhibits Helicobacter growth in vivo and in vitro. Int J Antimicrob Agents 2009; 33: 473-478 [PMID: 19157800 DOI: 10.1016/j.ijantimica g.2008.10.032]
161. Matsubara S, Shibata H, Ishikawa F, Yokokura T, Takahashi M, Sugimura T, Wakabayashi K. Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun 2003; 310: 715-719 [PMID: 14550260 DOI: 10.1016/j.bbrc.2003.09.066]
162. Mahady GB, Pendland SL, Chadwick LR. Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am J Gastroenterol 2003; 98: 1440-1441 [PMID: 12818294 DOI: 10.1111/j.1572-0241.2003.07513.x]
163. Paulo L, Oleastro M, Gallardo E, Queiroz JA, Domingues F. Anti-Helicobacter pylori and urease inhibitory activities of resveratrol and red wine. Food Res Int 2011; 44: 964-969 [DOI: 10.1016/j.foodres.2011.02.017]
164. Ruggiero P, Rossi G, Tombola F, Pancotto L, Lauretti L, Del Giudice G, Zoratti M. Red wine and green tea reduce H pylorior VacA-induced gastritis in a mouse model. World J Gastroenterol 2007; 13: 349-354 [PMID: 17230601]
165. Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Anti-Helicobacter pylori flavonoids from licorice extract. Life Sci 2002; 71: 1449-1463 [PMID: 12127165 DOI: 10.1016/ S0024-3205(02)01864-7]
166. Krausse R, Bielenberg J, Blaschek W, Ullmann U. In vitro anti-Helicobacter pylori activity of Extractum liquiritiae, glycyrrhizin and its metabolites. J Antimicrob Chemother 2004; 54: 243-246 [PMID: 15190039 DOI: 10.1093/jac/dkh287]
167. Kim JM, Zheng HM, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori Properties of Gut Gard. Prev Nutr Food Sci 2013; 18: 104-110 [DOI: 10.3746/pnf.2013.18.2.104]
168. Ali AT, Chowdhury MN, al Humayyd MS. Inhibitory effect of natural honey on Helicobacter pylori. Trop Gastroenterol 1991; 12: 139-143 [PMID: 1841451]
169. Osato MS, Reddy SG, Graham DY. Osmotic effect of honey on growth and viability of Helicobacter pylori. Dig Dis Sci 1999; 44: 462-464 [PMID: 10080135 DOI: 10.1023/ A:1026676517213]
170. Nzeako BC, Al-Namaani F. The antibacterial activity of honey on Helicobacter pylori. Sultan Qaboos Univ Med J 2006; 6: 71-76 [PMID: 21748138]
171. Ndip RN, Malange Takang AE, Echakachi CM, Malongue A, Akoachere JF, Ndip LM, Luma HN. In-vitro antimicrobial activity of selected honeys on clinical isolates of Helicobacter pylori. Afr Health Sci 2007; 7: 228-232 [PMID: 21499488]
172. Al Somal N, Coley KE, Molan PC, Hancock BM. Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey. J R Soc Med 1994; 87: 9-12 [PMID: 8308841]
173. Manyi-Loh CE, Clarke AM, Munzhelele T, Green E, Mk-wetshana NF, Ndip RN. Selected South African honeys and their extracts possess in vitro anti-Helicobacter pylori activity. Arch Med Res 2010; 41: 324-331 [PMID: 20851288 DOI: 10.1016/j.arcmed.2010.08.002]
174. Manyi-Loh CE, Clarke AM, Ndip RN. Detection of phytoconstituents in column fractions of n-hexane extract of Goldcrest honey exhibiting anti-Helicobacter pylori activity. Arch Med Res 2012; 43: 197-204 [PMID: 22560982 DOI: 10.1016/ j.arcmed.2012.04.006]
175. McGovern DP, Abbas SZ, Vivian G, Dalton HR. Manuka honey against Helicobacter pylori. J R Soc Med 1999; 92: 439 [PMID: 10656024]
176. Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E,Katsarov N, Mitov I, Krastev Z. Activity of Bulgarian propolis against 94 Helicobacter pylori strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol 2005; 54: 481-483 [PMID: 15824428 DOI: 10.1099/ jmm.0.45880-0]
177. Cui K, Lu W, Zhu L, Shen X, Huang J. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits Helicobacter pylori peptide deformylase activity. Biochem Biophys Res Commun 2013; 435: 289-294 [PMID: 23611786 DOI: 10.1016/j.bbrc.2013.04.026]
178. Banskota AH, Tezuka Y, Adnyana IK, Ishii E, Midorikawa K, Matsushige K, Kadota S. Hepatoprotective and anti-Helicobacter pylori activities of constituents from Brazilian propolis. Phytomedicine 2001; 8: 16-23 [PMID: 11292234 DOI: 10.1078/0944-7113-00004]
179. Coelho LG, Bastos EM, Resende CC, Paula e Silva CM, Sanches BS, de Castro FJ, Moretzsohn LD, Vieira WL, Trindade OR. Brazilian green propolis on Helicobacter pylori infection. a pilot clinical study. Helicobacter 2007; 12: 572-574 [PMID: 17760728 DOI: 10.1111/j.1523-5378.2007.00525.x]
180. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria 2001. FAO/WHO, Cordoba, Argentina
181. Chenoll E, Casinos B, Bataller E, Astals P, Echevarría J, Iglesias JR, Balbarie P, Ramón D, Genovés S. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol 2011; 77: 1335-1343 [PMID: 21169430 DOI: 10.1128/ AEM.01820-10]
182. Lorca GL, Wadström T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol 2001; 42: 39-44 [PMID: 11116395 DOI: 10.1007/ s002840010175]
183. Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004; 70: 518-526 [PMID: 14711683 DOI: 10.1128/ AEM.70.1.518-526.2004]
184. Pinchuk IV, Bressollier P, Verneuil B, Fenet B, Sorokulova IB, Mégraud F, Urdaci MC. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 2001; 45: 3156-3161 [PMID: 11600371 DOI: 10.1128/AAC.45.11.3156-3161.2001]
185. Nam H, Ha M, Bae O, Lee Y. Effect of Weissella confuse strain PL9001 on the adherence and growth of Helicobacter pylori. Appl Environ Microbiol 2002; 68: 4642-4645 [PMID: 12200324 DOI: 10.1128/AEM.68.9.4642-4645.2002]
186. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte cocultures. Gut 2000; 47: 79-87 [PMID: 10861268 DOI: 10.1136/ gut.47.1.79]
187. Johnson-Henry KC, Mitchell DJ, Avitzur Y, Galindo-Mata E, Jones NL, Sherman PM. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004; 49: 1095-1102 [PMID: 15387328]
188. Patel A, Shah N, Prajapati JB. Clinical appliance of probiotics in the treatment of Helicobacter pylori infection-A brief review. J Microbiol Immunol Infect 2013 Jun 8; Epub ahead of print [PMID: 23757373 DOI: 10.1016/j.jmii.2013.03.010]
189. Dekker KA, Inagaki T, Gootz TD, Huang LH, Kojima Y, Kohlbrenner WE, Matsunaga Y, McGuirk PR, Nomura E, Sakakibara T, Sakemi S, Suzuki Y, Yamauchi Y, Kojima N. New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activities. J Antibiot (Tokyo) 1998; 51: 145-152 [PMID: 9544935 DOI: 10.7164/antibiotics.51.145]
190. Dekker KA, Inagaki T, Gootz TD, Kaneda K, Nomura E, Sakakibara T, Sakemi S, Sugie Y, Yamauchi Y, Yoshikawa N, Kojima N. CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina: fermentation, isolation, structural elucidation and biological activities. J Antibiot (Tokyo) 1997; 50: 833-839 [PMID: 9402988 DOI: 10.7164/antibiotics.50.833]
191. Shang X, Tan Q, Liu R, Yu K, Li P, Zhao GP. In vitro anti-Helicobacter pylori effects of medicinal mushroom extracts, with special emphasis on the Lion's Mane mushroom, Hericium erinaceus (higher Basidiomycetes). Int J Med Mushrooms 2013; 15: 165-174 [PMID: 23557368 DOI: 10.1615/IntJMedMushr.v15.i2.50]
192. Geethangili M, Fang SH, Lai CH, Rao YK, Lien HM, Tzeng YM. Inhibitory effect of Antrodia camphorata constituents on the Helicobacter pylori-associated gastric inflammation. Food Chemistry 2010; 119: 149-153 [DOI: 10.1016/j.foodchem.2009.06.006]
193. Lin CJ, Rao YK, Hung CL, Feng CL, Lane HY, Tzeng DT, Hsu PN, Lai CH, Tzeng YM. Inhibition of Helicobacter pylori CagA-Induced Pathogenesis by Methylantcinate B from Antrodia camphorata. Evid Based Complement Alternat Med 2013; 2013: 682418 [PMID: 23431343 DOI: 10.1155/2013/682418]
194. Lachter J, Yampolsky Y, Gafni-Schieber R, Wasser SP. Yellow brain culinary-medicinal mushroom, Tremella mesenterica Ritz.: Fr. (higher Basidiomycetes), is subjectively but not objectively effective for eradication of Helicobacter pylori: a prospective controlled trial. Int J Med Mushrooms 2012; 14: 55-63 [PMID: 22339708 DOI: 10.1615/IntJMedMushr.v14. i1.60]
195. Kanamaru T, Nakano Y, Toyoda Y, Miyagawa KI, Tada M, Kaisho T, Nakao M. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother 2001; 45: 2455-2459 [PMID: 11502514 DOI: 10.1128/AAC.45.9.2455-2459.2001]
196. Vecchione JJ, Sello JK. A novel tryptophanyl-tRNA synthetase gene confers high-level resistance to indolmycin. Antimicrob Agents Chemother 2009; 53: 3972-3980 [PMID: 19546369 DOI: 10.1128/AAC.00723-09]
197. Iwahori A, Hirota Y, Sampe R, Miyano S, Takahashi N, Sasatsu M, Kondo I, Numao N. On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Biol Pharm Bull 1997; 20: 805-808 [PMID: 9255424 DOI: 10.1248/bpb.20.805]
198. Chen L, Li Y, Li J, Xu X, Lai R, Zou Q. An antimicrobial peptide with antimicrobial activity against Helicobacter pylori. Peptides 2007; 28: 1527-1531 [PMID: 17698252 DOI: 10.1016/ j.peptides.2007.07.007]
199. Numao N, Hirota Y, Iwahori A, Sasatsu M, Kondo I, Takao K, Kobayashi S. Antibacterial activity of (+/-) 6-benzyl-1-(3-carboxypropyl) indane; a possible way to identify leading novel anti-H. pylori agents. Biol Pharm Bull 1997; 20: 1204-1207 [PMID: 9401733 DOI: 10.1248/bpb.20.1204]
200. Bajaj-Elliott M, Fedeli P, Smith GV, Domizio P, Maher L, Ali RS, Quinn AG, Farthing MJ. Modulation of host antimicrobial peptide (beta-defensins 1 and 2) expression during gastritis. Gut 2002; 51: 356-361 [PMID: 12171956 DOI: 10.1136/ gut.51.3.356]
201. Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, Obonyo M, Gallo RL, Eckmann L, Kagnoff MF. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 2003; 125: 1613-1625 [PMID: 14724813 DOI: 10.1053/j.gastro.2003.08.028]
202. Rigano MM, Romanelli A, Fulgione A, Nocerino N, D'Agostino N, Avitabile C, Frusciante L, Barone A, Capuano F, Capparelli R. A novel synthetic peptide from a tomato defensin exhibits antibacterial activities against Helicobacter pylori. J Pept Sci 2012 Nov 4; Epub ahead of print [PMID: 23124812 DOI: 10.1002/psc.2462]
203. Lee H, Kobayashi M, Wang P, Nakayama J, Seeberger PH, Fukuda M. Expression cloning of cholesterol alpha-glucosyl-transferase, a unique enzyme that can be inhibited by natural antibiotic gastric mucin O-glycans, from Helicobacter pylori. Biochem Biophys Res Commun 2006; 349: 1235-1241 [PMID: 16978585 DOI: 10.1016/j.bbrc.2006.08.145]
204. Lindén SK, Wickström C, Lindell G, Gilshenan K, Carlstedt I. Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches. Helicobacter 2008; 13: 81-93 [PMID: 18321298 DOI: 10.1111/ j.1523-5378.2008.00587.x]
205. Shibata H, Iimuro M, Uchiya N, Kawamori T, Nagaoka M, Ueyama S, Hashimoto S, Yokokura T, Sugimura T, Wakabayashi K. Preventive effects of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2003; 8: 59-65 [PMID: 12603617 DOI: 10.1046/ j.1523-5378.2003.00124.x]
206. Loke MF, Lui SY, Ng BL, Gong M, Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Microbiol 2007; 50: 231-238 [PMID: 17521357 DOI: 10.1111/ j.1574-695X.2007.00248.x]
207. Lee JH, Shim JS, Lee JS, Kim JK, Yang IS, Chung MS, Kim KH. Inhibition of pathogenic bacterial adhesion by acidic polysaccharide from green tea (Camellia sinensis). J Agric Food Chem 2006; 54: 8717-8723 [PMID: 17090112 DOI: 10.1021/jf061603i]
208. Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol 2009; 125: 218-223 [PMID: 19607905 DOI: 10.1016/j.jep.2009.07.009]
209. Lengsfeld C, Deters A, Faller G, Hensel A. High molecular weight polysaccharides from black currant seeds inhibit adhesion of Helicobacter pylori to human gastric mucosa. Planta Med 2004; 70: 620-626 [PMID: 15254855 DOI: 10.1055/s-2004-827184]
210. Lembo AJ, Ganz RA, Sheth S, Cave D, Kelly C, Levin P, Kazlas PT, Baldwin PC, Lindmark WR, McGrath JR, Hamblin MR. Treatment of Helicobacter pylori infection with intra-gastric violet light phototherapy: a pilot clinical trial. Lasers Surg Med 2009; 41: 337-344 [PMID: 19533762 DOI: 10.1002/lsm.20770]